Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient

Table 5 Arsenic concentrations in PB and BM plasma collected during the remission induction therapy

Days after the start of administration		-1		14		28		42		56
Clinical samples		PB	BM	PB	BM	PB	BM	PB	BM	PB	BM
Arseni concentrations (ngAs/g)	As(V)	0.36	0.35	1.26	0.54	1.50	1.91	0.99	2.34	0.24	0.17
	As(III)	0	0	6.31	3.43	7.89	7.47	5.83	4.00	0.09	0.10
	MA(V)	0.55	0.80	10.6	12.4	13.5	12.4	14.0	13.0	1.87	1.63
	DMA(V)	0.11	0.63	13.2	11.5	13.3	12.1	15.3	15.1	3.96	3.21
	AB	0.60	0.51	0.43	3.49	3.80	0.50	0.99	0.99	1.22	1.00

Blood samples and BM aspirations were collected before the treatment start (day -1), and 14, 28, 42, and 56 days after the start of administration. The concentrations of arsenic species in PB and BM plasma were determined by HPLC/ICP-MS as described in "Patient and Methods".

ISSN: 1756-8722